trenbolone acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids not used as glucocorticosteroids | 5636 | 10161-34-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An anabolic steroid used mainly as an anabolic agent in veterinary practice
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D045930 | Anabolic Agents |
| MeSH PA | D006728 | Hormones |
| CHEBI has role | CHEBI:76924 | plant metabolites |
| CHEBI has role | CHEBI:138015 | endocrine disruptors |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | To increase rate of weight gain | Indication |
| Cattle | To improve feed efficiency | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Finaplix-H, Finaplix-S | Intervet Inc. | 1 |
| Revalor-G, Revalor-IS, Revalor-S | Intervet Inc. | 2 |
| Revalor-200, Revalor-H, Revalor-IH | Intervet Inc. | 2 |
| SYNOVEX Choice, SYNOVEX PLUS | Zoetis Inc. | 2 |
| Revalor-XH, Revalor-XS | Intervet Inc. | 2 |
| SYNOVEX ONE FEEDLOT, SYNOVEX ONE Grower | Zoetis Inc. | 2 |
| Revalor-XR | Intervet Inc. | 2 |
| Component TE-G, Component TE-G with Tylan, Component TE-ID with Tylan, Component TE-IS, Component TE-IS with Tylan, Component TE-S, Component TE-S with Tylan | Elanco US Inc. | 3 |
| Component T-H with Tylan, Component T-S with Tylan | Elanco US Inc. | 2 |
| Component TE-200 with Tylan, Component TE-H with Tylan, Component TE-IH with Tylan | Elanco US Inc. | 3 |
| Synovex T120, Synovex T40, Synovex T80 | Zoetis Inc. | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Polymerase acidic protein | Enzyme | Kd | 4.04 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| CHEBI:35018 | CHEBI |
| CHEMBL1698011 | ChEMBL_ID |
| DB14660 | DRUGBANK_ID |
| DB11551 | DRUGBANK_ID |
| 005817 | NDDF |
| D014204 | MESH_DESCRIPTOR_UI |
| C0076958 | UMLSCUI |
| 117059000 | SNOMEDCT_US |
| 96344003 | SNOMEDCT_US |
| 2916 | INN_ID |
| 10161-33-8 | SECONDARY_CAS_RN |
| D06211 | KEGG_DRUG |
| 66359 | PUBCHEM_CID |
| 25015 | PUBCHEM_CID |
| 1484277 | RXNORM |
| RUD5Y4SV0S | UNII |
| P53R4420TR | UNII |
Pharmaceutical products:
None